ADC Therapeutics SA Hits New 52-Week High of $4.95, Up 31.87%

ADC Therapeutics SA has reached a significant milestone by hitting a new 52-week high of USD 4.95 on March 10, 2026. This achievement marks a notable increase from its 52-week low of USD 1.05, reflecting a robust performance over the past year. The stock has demonstrated a remarkable 31.87% increase in value, significantly outperforming the S&P 500, which recorded a gain of 20.78% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, ADC Therapeutics SA has a market capitalization of USD 518 million. The company has shown impressive financial metrics, including a return on equity of 68.82%. However, it is important to note that the company is currently loss-making, with a price-to-earnings ratio not applicable. Additionally, the company does not offer a dividend, and its debt-to-equity ratio stands at -0.93, indicating a unique financial structure. This recent price movement highlights ADC Therapeutics SA's position within the market and its performance relative to broader industry trends.